Marek Ciszewski

Marek Ciszewski, JD, currently serves as Chief Financial Officer at NImmune Biopharma, Inc., leading the program Omilancor in a Phase 3 global registration directed for Ulcerative Colitis. With extensive experience in the biopharmaceutical sector, Marek also holds the position of Entrepreneur in Residence and Head of Investments at MediCari Ventures, focusing on biopharmaceutical firms leveraging AI/ML for drug discovery. Previous roles include Senior Vice President of Investor Relations & Corporate Communications at Coherus BioSciences, Vice President of Financial Strategy and Investor Relations at Landos Biopharma, and Head of Investor Relations at Lantern Pharma. Additionally, Marek has served on the board of Murrieta Genomics and has held senior positions at Gateway Group, EPIRUS Biopharmaceuticals, and Verastem Oncology, as well as being the Global Head of Healthcare Investment Research at BMO Global Asset Management U.S. Educational credentials include a JD from Chicago-Kent College of Law and multiple degrees from DePaul University, with a Master of Science in Accounting currently in progress.